High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma

Purpose We have previously demonstrated a significant negative impact of intratumoral neutrophils in metastatic renal cell carcinoma. This study assessed intratumoral neutrophils in localized clear cell renal cell carcinoma (RCC). Patients and Methods The study comprised 121 consecutive patients who had a nephrectomy for localized RCC. Biomarkers (intratumoral CD8+, CD57+ immune cells, CD66b+ neutrophils, and carbonic anhydrase IX [CA IX]) were assessed by immunohistochemistry, and the relationship with clinical and histopathologic features and patient outcome was evaluated. Results The intratumoral neutrophils ranged from zero to 289 cells/mm2 tumor tissue. The presence of intratumoral neutrophils was statistically significantly associated with increasing tumor size, low hemoglobin, high creatinine, and CA IX ≤ 85%. In multivariate analysis, the presence of intratumoral neutrophils (hazard ratio [HR], 3.0; 95% CI, 1.7 to 5.4; P < .0001), pT stage T3b/T4 (HR, 2.1; 95% CI, 1.2 to 3.6; P = .007), and low hemoglobin (HR, 1.8; 95% CI, 1.0 to 3.1; P = .03) were independent prognostic factors significantly associated with short recurrence-free survival. The presence of intratumoral neutrophils was also an independent prognostic factor for cancer-specific survival (HR, 3.5; 95% CI, 1.9 to 6.4; P < .0001) and overall survival (HR, 3.1; 95% CI, 1.9 to 5.0; P < .0001). Applying the prognostic value of intratumoral neutrophils to the Leibovich low-/intermediate-risk group (n = 78) showed a 5-year recurrence-free survival of 53% (95% CI, 34.6% to 71.8%; presence of intratumoral neutrophils) versus 87% (95% CI, 77.8% to 96.8%; absence of intratumoral neutrophils). The estimated concordance index was 0.74 using the Leibovich risk score and 0.80 when intratumoral neutrophils were added. Conclusion The presence of intratumoral neutrophils is a new, strong, independent prognostic factor for short recurrence-free, cancer-specific, and overall survival in localized clear cell RCC.

Download Full-text

Circulating tumor cell (CTC) as a significant prognostic factor in resected primary lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e23044 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e23044-e23044 ◽

Cited By ~ 1

Author(s):

Kazue Yoneda ◽

Masaki Hashimoto ◽

Teruhisa Takuwa ◽

Seiji Matsumoto ◽

Yoshitomo Okumura ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Multivariate Analysis ◽

Survival Rate ◽

Primary Lung Cancer ◽

Circulating Tumor Cell ◽

Small Cell ◽

Recurrence Free Survival ◽

Poor Overall Survival ◽

Free Survival

e23044 Background: Circulating tumor cell (CTC) is a potentially useful marker in early diagnosis and monitoring therapeutic effects for patients with malignant tumors, but clinical significance of CTC in primary lung cancer remains unclear. We previously showed that CTC was a useful surrogate marker of distant metastasis in primary lung cancer (Clin Cancer Res 2009). In this study, we evaluated the prognostic value among completely resected patients after long-term follow-up. Methods: A total of 94 patients (median age, 68 years; 30 females and 64 males) who underwent complete resection for primary lung cancer (4 with small cell and 90 with non-small cell) were prospectively evaluated. At the time of enrollment into the study, 7.5mL of peripheral blood was sampled from each patient, and an EpCAM-based detection system (CellSearch) was used for detection of CTC. CTC was detected in 16 patients (CTC-positive, 14.9%). Results: CTC-positivity was significantly associated with a poor recurrence-free survival (5-year recurrence-free survival rate, 40% versus 72%; p<0.01) (Table 1), which was confirmed by a multivariate analysis (hazard ratio, 2.57 [95% CI, 1.26-5.26]; P=0.010). CTC-positivity was also associated with a poor overall survival (5-year recurrence-free survival rate, 62% versus 84%; p<0.05) (Table 1), which was confirmed by a multivariate analysis (hazard ratio, 2.76 [95% CI, 1.14-6.71]; P=0.025). Conclusions: CTC-positivity was associated with poor recurrence-free survival and poor overall survival in resected lung cancer. [Table: see text]

Download Full-text

High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent‐free survival in head and neck squamous cell carcinoma

Journal of Clinical Laboratory Analysis ◽

10.1002/jcla.23107 ◽

2020 ◽

Vol 34 (3) ◽

Cited By ~ 2

Author(s):

Qun Li ◽

Zhisen Shen ◽

Zhenhua Wu ◽

Yi Shen ◽

Hongxia Deng ◽

...

Keyword(s):

Overall Survival ◽

Squamous Cell Carcinoma ◽

Prognostic Factor ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Independent Prognostic Factor ◽

Neck Squamous Cell Carcinoma ◽

Poor Overall Survival ◽

Free Survival

Download Full-text

Comparison of uniportal video-assisted thoracoscopic versus thoracotomy bronchial sleeve lobectomy with pulmonary arterioplasty for centrally located non-small-cell lung cancer

European Journal of Cardio-Thoracic Surgery ◽

10.1093/ejcts/ezaa404 ◽

2020 ◽

Author(s):

Dong Xie ◽

Yifan Zhong ◽

Deng ◽

Yunlang She ◽

Lei Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Recurrence Free Survival ◽

Small Cell Lung ◽

Sleeve Lobectomy ◽

Free Survival ◽

Video Assisted

Abstract OBJECTIVES This study aimed to investigate the efficacy of bronchial sleeve lobectomy with pulmonary arterioplasty by uniportal video-assisted thoracoscopic surgery (UniVATS) in centrally located non-small-cell lung cancer. METHODS One hundred and two thoracotomy and 31 UniVATS cases were included in this retrospective, single-centre study. Baseline characteristics, perioperative performance and survival outcomes were compared between the 2 groups. RESULTS Compared with the thoracotomy group, the UniVATS group was associated with lower postoperative blood transfusion rate (P = 0.043), decreased postoperative hospital stays (P = 0.008), shorter drainage duration (P = 0.003) and less drainage volume during the first postoperative 24 h (P = 0.005). Besides, the 3-year overall survival and recurrence-free survival were comparable between the 2 groups (log-rank, P = 0.81 and P = 0.78, respectively). In addition, squamous cell carcinoma was proved to be the independent favourable predictor for overall survival [hazard ratio (HR) 0.44, 95% confidence interval (CI) 0.24–0.80; P = 0.008], and advanced pathological stage was found to be independently associated with worse overall survival (IIIB stage: HR 3.21, 95% CI 1.13–9.12; P = 0.028) and recurrence-free survival (IIIB stage: HR 3.54, 95% CI 1.32–9.51; P = 0.012). CONCLUSIONS With appropriate patient selection, UniVATS sleeve lobectomy with pulmonary arterioplasty is feasible and safe for centrally located lung cancer in the hands of thoracic surgeons with extensive thoracoscopy experience.

Download Full-text

Number of metastatic lymph nodes and zones as prognostic factors in non-small-cell lung cancer

Interactive CardioVascular and Thoracic Surgery ◽

10.1093/icvts/ivaa107 ◽

2020 ◽

Vol 31 (3) ◽

pp. 305-314

Author(s):

Tomohiro Maniwa ◽

Akiisa Ohmura ◽

Takashi Hiroshima ◽

Akihiro Ike ◽

Toru Kimura ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Prognostic Factors ◽

Small Cell ◽

Recurrence Free Survival ◽

Small Cell Lung ◽

Free Survival ◽

Nsclc Patients ◽

Relationship Of ◽

The Relationship

Abstract OBJECTIVES Characterizing pathological nodes (pNs) by location alone is sometimes inadequate as patients with pN1 or pN2 non-small-cell lung cancer (NSCLC) show prognostic heterogeneity. We aimed to assess the relationship of the number of metastatic lymph nodes (LNs) and zones with prognosis in NSCLC patients. METHODS We analysed 1393 patients who underwent lobectomy with mediastinal LN dissection for NSCLC at the Osaka International Cancer Institute between January 2006 and December 2015. Patients were classified into 3 groups according to the number of LNs: n1–3, n4–6 and n7–. We investigated the relationship of prognosis with the number of metastatic LNs and metastatic zones. RESULTS In the multivariable analyses, the number of metastatic LNs and zones were not independent factors for overall survival or recurrence-free survival in patients with pN1 disease after adjustment for age, sex, tumour histology and tumour diameter. However, n4–6 (ref. n1–3) was an independent prognostic factor for overall survival [hazard ratio (HR) 4.148, P < 0.001] in those with pN2 disease. There were no significant differences in overall survival and recurrence-free survival between pN1 (HR 0.674, P = 0.175) and pN2n1–3 disease (HR 1.056, P = 0.808). Moreover, patients with pN2 disease with a higher number of metastatic zones had a poor prognosis for recurrence-free survival [3 zones (ref. 1): HR 1.774, P = 0.051, and 4 zones (ref. 1): HR 2.173, P < 0.047]. CONCLUSIONS The number of metastatic LNs and metastatic zones were useful prognostic factors in NSCLC patients. The findings could help in establishing a new pN classification.

Download Full-text

Increased expression of SLC35F2 in non-small cell lung cancer predicts poor prognosis

10.21203/rs.2.22980/v1 ◽

2020 ◽

Author(s):

Peng Wei ◽

Zhenjie Huang ◽

Guangnan Liu

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Prognostic Factor ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Poor Prognosis ◽

Small Cell ◽

Independent Prognostic Factor ◽

Gene Set Enrichment Analysis ◽

Small Cell Lung

Abstract Background: Although previous studies have documented the expression of Homo sapiens solute carrier family 35 member F2 (SLC35F2) in NSCLC, its prognostic value for NSCLC has not been reported.Methods: We performed Wilcoxon signed-rank test and logistic regression to investigate the correlations between SLC35F2 expression and clinical parameters. A Cox regression was used to investigate the association between clinical features and overall survival (OS). Gene Set Enrichment Analysis (GSEA) was performed to further understand the pathways involved in NSCLC pathogenesis related SLC35F2.Results: In LUAD, increased expression of SLC35F2 was associated with stage (OR = 1.53 for stage III-IV vs. Stage I-II), N stage (OR = 1.62 for N1-3 vs. N0), and residual tumor (OR = 5.00 for with tumor vs. Tumor free) (p <0.05). The Kaplan-Meier curve showed that the prognosis of SLC35F2-high NSCLC was worse than that of SLC35F2-low. For LUAD, the univariate analysis showed that increased expression of SLC35F2 was associated with a poor overall survival (HR 1.04; 95% CI 1.00-1.08; p = 0.04). Multivariate analysis showed that SLC35F2 can be used as an independent prognostic factor for LUAD. GSEA show that P53 signal pathway and apoptosis are signiﬁcantly enriched in SLC35F2-high in NSCLC.Conclusions: Increased expression of SLC35F2 in non-small cell lung cancer predicts poor prognosis. Moreover, SLC35F2 can be used as an independent prognostic factor for LUAD.

Download Full-text